Show simple item record

dc.contributor.authorLynch, Maeve
dc.contributor.authorAhern, Tomás B
dc.contributor.authorTimoney, Irene
dc.contributor.authorSweeney, Cheryl
dc.contributor.authorKelly, Genevieve
dc.contributor.authorHughes, Rosalind
dc.contributor.authorTobin, Anne-Marie
dc.contributor.authorO'Shea, Donal
dc.contributor.authorKirby, Brian
dc.date.accessioned2017-03-03T12:20:13Z
dc.date.available2017-03-03T12:20:13Z
dc.date.issued15/01/2016
dc.identifier.citationDipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial. 2016, 17:29 Trialsen
dc.identifier.issn1745-6215
dc.identifier.pmid26767505
dc.identifier.doi10.1186/s13063-016-1157-z
dc.identifier.urihttp://hdl.handle.net/10147/621122
dc.description.abstractModerate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic disease.
dc.language.isoenen
dc.publisherBioMed Central Trialsen
dc.rightsArchived with thanks to Trialsen
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en
dc.subjectPSORIASISen
dc.subjectSKIN DISORDERSen
dc.subject.meshClinical Protocols
dc.subject.meshDipeptidyl-Peptidase IV Inhibitors
dc.subject.meshHumans
dc.subject.meshProspective Studies
dc.subject.meshPsoriasis
dc.subject.meshQuality Control
dc.subject.meshSample Size
dc.subject.meshSitagliptin Phosphate
dc.subject.meshUltraviolet Therapy
dc.titleDipeptidyl peptidase-4 inhibition and narrow-band ultraviolet-B light in psoriasis (DINUP): study protocol for a randomised controlled trial.en
dc.typeArticleen
dc.identifier.journalTrialsen
dc.description.fundingOtheren
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
refterms.dateFOA2018-08-27T19:46:35Z
html.description.abstractModerate to severe psoriasis is a systemic inflammatory disease associated with insulin resistance, obesity and type 2 diabetes (T2DM). Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that improves glycaemia and has a marketing authorisation for the treatment of T2DM. Non-immunosuppressive therapies that are effective for psoriasis and its associated comorbidities would be a significant advance in the treatment of this chronic disease.


Files in this item

Thumbnail
Name:
DINUPStudyProtocol.pdf
Size:
570.5Kb
Format:
PDF
Description:
OA Article

This item appears in the following Collection(s)

Show simple item record

Archived with thanks to Trials
Except where otherwise noted, this item's license is described as Archived with thanks to Trials